The Company

Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company, recognising the considerable therapeutic potential of Lamellasomes™ and acquired the intellectual property rights to the technology.

The Company benefits from having an entrepreneurial Board of Directors and Management Team, a Scientific Advisory Board of eminent scientists and a Research Team with intimate knowledge of lamellar body physiology and pathology.

The Company also enjoys the continuing input of Dr James W Dobbie who has pioneered research into lamellar bodies over many years.

Electron micrograph of
Lamellasome vesticles

The Company enjoys the financial backing of the business angel organisations, Barwell Plc and TRI Capital Limited, together with a number of private investors and matching support from the Scottish Co-Investment Fund.

Located on the Strathclyde Business Park, Bellshill, United Kingdom and within easy access to international airports, the Company operates from modern, well equipped laboratories and offices. Alongside our own research and collaborations with industrial and academic partners, we are also able to offer services in electron microscopy. Development activities are currently out-sourced to world-class, experienced and accredited contract research and manufacturing organisations.

Intellectual property protects the use of Lamellasome™ multi-lamellar vesicles for therapeutic purposes. Patent families are being developed to protect the Company’s intellectual property. Trade Mark Registrations in relation to the Lamellasome™ mark have been pursued in the United Kingdom, United States of America and Europe.